GRAIL Inc. Common Stock (GRAL)
Stock · NASDAQ · Health Care
$117.74as of 10/16/2026
Price chart
Active signals
GRAL Signal Track Record
How signals performed across all stocks →What GRAL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 14 | -0.4% | 50% | September 21, 2026 |
| Volume Spike | 13 | +6.0% | 62% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +8.0% | 60% | August 19, 2026 |
| Bollinger Band Breakdown | 4 | +8.4% | 50% | July 28, 2026 |
| Any 20-session window (baseline) | +9.9% | 70% |
Computed by MarketWall from daily closing prices since March 31, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, inc…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 910
- Website
- grail.com/
Fundamentals
- 1-day range
- $132.09$139.5
- Market cap
- $2.72B
- P/E (trailing)
- —
- P/E (forward)
- -16.42
- EPS (trailing)
- $-9.75
- Dividend yield
- —
- Beta
- 1.88
- Avg. volume
- 967.2K
How GRAIL Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
GRAIL Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- GRALGRAIL Inc. Common Stock$117.81▼ 13.03%Market cap $2.72BP/E —$41.5$166.48
- ALHCAlignment Healthcare Inc. Common Stock$8.28▲ 1.60%Market cap $2.78BP/E 41.54$6.01$25.12
- ACHCAcadia Healthcare Company Inc. Common Stock$29.98▼ 3.41%Market cap $2.86BP/E —$11.43$35.83
- CLOVClover Health Investments Corp. Class A Common Stock$4.48▼ 4.27%Market cap $2.45BP/E —$1.58$5.59
- CDNACareDx Inc. Common Stock$64▼ 4.01%Market cap $2.32BP/E 30.15$14.03$72.51
- VCYTVeracyte Inc. Common Stock$43.12▼ 2.86%Market cap $3.71BP/E 31.17$29.46$60.91
- FTREFortrea Holdings Inc. Common Stock$22.49▼ 1.12%Market cap $1.68BP/E —$8.55$23.51
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GRAL GRAIL Inc. Common Stock | $2.72B | — | $117.81 | ▼ 13.03% | $41.5$166.48 |
| ALHC Alignment Healthcare Inc. Common Stock | $2.78B | 41.54 | $8.28 | ▲ 1.60% | $6.01$25.12 |
| ACHC Acadia Healthcare Company Inc. Common Stock | $2.86B | — | $29.98 | ▼ 3.41% | $11.43$35.83 |
| CLOV Clover Health Investments Corp. Class A Common Stock | $2.45B | — | $4.48 | ▼ 4.27% | $1.58$5.59 |
| CDNA CareDx Inc. Common Stock | $2.32B | 30.15 | $64 | ▼ 4.01% | $14.03$72.51 |
| VCYT Veracyte Inc. Common Stock | $3.71B | 31.17 | $43.12 | ▼ 2.86% | $29.46$60.91 |
| FTRE Fortrea Holdings Inc. Common Stock | $1.68B | — | $22.49 | ▼ 1.12% | $8.55$23.51 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Jim Cramer Breaks Down the Stakes in Detail as GRAIL (GRAL) Awaits Its Next Big DecisionYahoo · 10/10/2026
- Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy?Yahoo · 10/9/2026
- 2 Growth Stocks to Buy in OctoberYahoo · 10/8/2026
- Why CVS Is ‘Insanely Cheap,’ ON Semi a Laggard Catching Up, and Grail Too Expensive to ChaseYahoo · 10/7/2026
- GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026Yahoo · 10/5/2026
- Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)Yahoo · 10/4/2026
- Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?Yahoo · 10/4/2026
- Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial ResultsYahoo · 10/3/2026
- Grail Analyst Sees Massive Market Potential with Valuation Headwindsbenzinga · 9/18/2026
Insider Activity
Insider Actions →- Andrew John Partridge · October 5, 2026 · Sale7.9K @ $146.39
- Aaron Freidin · October 5, 2026 · Sale23.6K @ $146.39
- Joshua J. Ofman · September 21, 2026 · Sale6.2K @ $96.43
- Aaron Freidin · September 21, 2026 · Sale521 @ $95
- Aaron Freidin · September 21, 2026 · Sale1.8K @ $93.92
- Aaron Freidin · September 21, 2026 · Sale1.8K @ $92.26
- Joshua J. Ofman · September 21, 2026 · Option Exercise26.5K @ $14
- Joshua J. Ofman · September 21, 2026 · Sale10.0K @ $110
- Joshua J. Ofman · September 21, 2026 · Sale2.1K @ $100.68
- Joshua J. Ofman · September 21, 2026 · Sale421 @ $99.85
- Joshua J. Ofman · September 21, 2026 · Sale1.4K @ $97.84
- Joshua J. Ofman · September 21, 2026 · Sale37.8K @ $94.98
- Joshua J. Ofman · September 21, 2026 · Sale1.5K @ $93.61
- Joshua J. Ofman · September 21, 2026 · Sale2.1K @ $92.32
- Joshua J. Ofman · August 27, 2026 · Sale5.0K @ $85.02
Institutional Ownership
March 31, 2026
- Total shares held
- 36.58M
- Total value held
- $1.89B
- Institutional holders
- 358
- Unknown4.03M
- Unknown3.25M
- Unknown2.97M
- Unknown1.89M
- Unknown1.84M
- Unknown1.72M
- Unknown1.72M
- Unknown1.63M
- Unknown1.53M
- Unknown1.31M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Grail hits 12-month high after FDA panel win
Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.
Grail hits 12-month high after FDA panel win. Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.